Ani Pharmaceuticals Stock Price To Sales
| BSFA Stock | 54.00 1.50 2.70% |
ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.
ANI |
ANI Pharmaceuticals Company Price To Sales Analysis
ANI Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current ANI Pharmaceuticals Price To Sales | 2.23 X |
Most of ANI Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, ANI Pharmaceuticals has a Price To Sales of 2.232 times. This is 89.57% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The price to sales for all Germany stocks is 80.46% higher than that of the company.
ANI Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.ANI Pharmaceuticals is currently under evaluation in price to sales category among its peers.
ANI Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0374 | |||
| Profit Margin | (0.24) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 894.88 M | |||
| Shares Outstanding | 17.45 M | |||
| Shares Owned By Insiders | 13.11 % | |||
| Shares Owned By Institutions | 75.34 % | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 2.23 X | |||
| Revenue | 216.14 M | |||
| Gross Profit | 117.43 M | |||
| EBITDA | 3.12 M | |||
| Net Income | (42.6 M) | |||
| Total Debt | 286.52 M | |||
| Book Value Per Share | 19.11 X | |||
| Cash Flow From Operations | 3.32 M | |||
| Earnings Per Share | (4.46) X | |||
| Number Of Employees | 601 | |||
| Beta | 1.06 | |||
| Market Capitalization | 699.18 M | |||
| Total Asset | 771.6 M | |||
| Z Score | 1.2 | |||
| Net Asset | 771.6 M |
About ANI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.